ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Gland Pharma's board approved re-appointment of an independent director, appointed a new independent director, and accepted a resignation. These changes strengthen board governance with experienced pharmaceutical leaders.
Gland Pharma Limited has scheduled a Board Meeting for May 15, 2026, to consider audited standalone and consolidated financial results for the year ended March 2026. The board will also consider a recommendation for a final dividend. The trading window is closed from March 28, 2026, until May 17, 2026.
Gland Pharma Limited has scheduled a Board Meeting for May 15, 2026, to approve audited financial results for FY 2025-26 and consider a final dividend. The company's trading window remains closed until May 18, 2026. An earnings call is also scheduled for the evening of May 15.
Gland Pharma Limited's Board approved the reappointment of Ms. Naina Lal Kidwai as an Independent Director for a second five-year term, effective May 17, 2026, to May 16, 2031. The reappointment is subject to shareholder approval via postal ballot.